P-300N: Advanced Silicon Battery Achieved Over 90% Capacity Retention at 300 Cycles in Full Cell Surpasses Targeted Performance of 80% Retention at 300 CyclesOne of Most Stable, Low-Cost Materials in Global Battery Supply Chain Dr. J.S. Jeoung Commits Full-Time as Senior Vice President of Commercialization & Cell Development Previous Experience in Achieving Commercial-Standard Performance for Silicon Battery Initiated Battery Cell Design for P-300N Long-Term Performance Testing in Large-Scale Battery Format ...

NeoGenomics (NEO) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Tycho Peterson from the Life Science Tools Group. It's my pleasure to introduce our next company this afternoon, NeoGenomics. Tony, I'm going to maybe open it up with you. You've had a little bit of time in the CEO role here. Just talk about early learnings, how you're kind of thinking about stepping in, any big changes that need to happen? Speaker1 No. I think it's been a really good introductory period for me. I had the op ...

Summary of NeoGenomics (NEO) FY Conference Call - June 03, 2025 Company Overview - **Company**: NeoGenomics - **CEO**: Tony Zuck, who joined a few months prior to the conference but has been associated with the company for two years as a board member [4][3] Industry Insights - **Cancer Statistics**: One in two men and one in three women will face cancer in their lifetime, highlighting the significant market for cancer diagnostics [7] - **Patient Treatment Preferences**: 80% of cancer patients prefer to be treated in their local community, which informs NeoGenomics' strategy to focus on community hospitals [9] Strategic Positioning - **Market Position**: NeoGenomics operates between large clinical reference labs and Oncotechs, with over 500 test offerings, focusing on oncology [10][12] - **Market Size**: The cancer diagnostic testing market is approximately $12 billion, with a penetration rate of 70%. The therapy selection market is about $13 billion with a 35% penetration rate, and the MRD market is estimated at $30 billion with only 5-8% penetration [13][15] Growth Strategy - **Community Focus**: The company aims to provide the same level of cancer care in community settings as found in top hospitals [10] - **Revenue Growth**: NeoGenomics has achieved 8% year-on-year growth in volume and anticipates continued growth driven by new product offerings and market expansion [34][44] - **Sales Force Expansion**: The sales force has been expanded to 140 representatives, focusing on oncology practices [35] Product Development - **New Product Launches**: The PANTRACER product suite, including liquid biopsy and tissue tests, is set to launch, enhancing the company's oncology portfolio [39][40] - **Research and Development**: Emphasis on next-generation precision diagnostic solutions, particularly in MRD and therapy selection [27][28] Financial Performance - **Revenue Growth**: Revenue increased from approximately $484 million in 2021 to over $660 million in 2024, with a positive EBITDA of $40 million [42][43] - **Future Projections**: Expected revenue growth of 13% to 15% for the current year, with adjusted EBITDA growth of 38% to 45% [44] Strategic Acquisitions - **Pathline Acquisition**: Acquired Pathline to strengthen the company's presence in the Northeast, enhancing service capabilities and turnaround times [37][46] Conclusion - **Optimistic Outlook**: The company is positioned for sustainable growth through its community-focused strategy, innovative product offerings, and operational efficiencies [48][49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics (NEO) Q1 2025 Earnings Call April 29, 2025 01:46 PM ET Speaker0 Greetings, and welcome to the NeoGenomics First Quarter twenty twenty five Conference Call. At this time, all participants are on a listen only mode, and a question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Kendra Sweeney, VP of Investor Relations. Ma'am, you may begin. Speaker1 Thank you, Ellie. Good morning, everyone, and ...

1Q 2025 Financial Results Nasdaq: NEO 1 April 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securit ...

Group 1 - NeoGenomics reported break-even quarterly earnings per share, surprising the market as the consensus estimate was a loss of $0.02, marking a 100% earnings surprise [1] - The company posted revenues of $168.04 million for the quarter ended March 2025, which was 1.66% below the Zacks Consensus Estimate, but an increase from $156.24 million year-over-year [2] - Over the last four quarters, NeoGenomics has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] Group 2 - NeoGenomics shares have declined approximately 39.5% since the beginning of the year, contrasting with the S&P 500's decline of 6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.04 on revenues of $183.07 million, and for the current fiscal year, it is $0.16 on revenues of $738.2 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact NeoGenomics' stock performance [5][6]

NeoGenomics (NEO) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Kendra Sweeney - Vice President of Investor Relations & CommunicationsTony Zook - CEOWarren Stone - President & COOAndrew Lukowiak - Chief Innovation OfficerJeffrey Sherman - Chief Financial OfficerDaniel Brennan - Managing DirectorMatthew Sykes - Financial AdvisorKareem Saad - Head of Strategy & TransformationMichael Ryskin - Managing DirectorAndrew Cooper - VP - Equity ResearchJack Melick - Equity Research AssociatePun ...

Fort Myers, Florida (April 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. Exhibit 99.1 NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million First Quarter 2025 Highlights As Compared To First Quarter 2024 "Our business is off to a solid start in 2025 with our team delivering a record number ...

Core Viewpoint - NEO Battery Materials Ltd. has appointed Mr. Kenneth Hoffman to its Board of Directors, bringing extensive expertise in battery materials and investment management to support the company's strategic initiatives in the battery market [1][4]. Company Overview - NEO Battery Materials is a Canadian company focused on developing low-cost silicon anode materials for lithium-ion batteries, aiming to enhance battery performance in electric vehicles, electronics, and energy storage systems [8]. Appointment of Kenneth Hoffman - Mr. Hoffman has over 30 years of experience in investment management, energy, and metals and mining, previously serving as the Global Head of Battery Materials at McKinsey & Company [2][3]. - His role at NEO will involve providing strategic support for industry partnerships, market expansion, and corporate development, leveraging his global network and understanding of the battery landscape [4]. Strategic Importance - The appointment is expected to reinforce NEO's position as a leading innovator in battery materials, particularly in the commercialization of its silicon anode technology [4][6]. - Mr. Hoffman emphasized the need for faster charging, lower-cost, and higher-density batteries, aligning with NEO's goals to improve silicon anode production [6]. Compensation Details - As part of his compensation, Mr. Hoffman has been granted stock options to acquire 300,000 common shares at an exercise price of $0.60, with vesting schedules outlined [6]. Upcoming Events - NEO Battery Materials will hold its Annual General and Special Meeting of Shareholders on June 4, 2025, where shareholders will have the opportunity to vote on company matters [7].